Future studies aimed at screening larger cohorts and refining the classification of BARD1 variants will help to elucidate its role as a breast and/or ovarian cancer gene as well as define medical recommendations for BARD1 PV carriers. Here, BARD1 is linked to ovarian carcinoma.